Quanterix Corp (NAS:QTRX)

$ 13.2 0.23 (1.77%) Market Cap: 506.60 Mil Enterprise Value: 240.50 Mil PE Ratio: 0 PB Ratio: 1.51 GF Score: 71/100

Q1 2024 Quanterix Corp Earnings Call Transcript
May 08, 2024

$16.51 (-4.90%)

Earnings
Q4 2023 Quanterix Corp Earnings Call Transcript
Feb 29, 2024

$23.96 (+2.04%)

Earnings
Quanterix Corp at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Q3 2023 Quanterix Corp Earnings Call Transcript
Nov 07, 2023

$22.54 (+2.18%)

Earnings
Quanterix Corp at Goldman Sachs Alzheimer's Disease Day Transcript
Oct 03, 2023
Quanterix Corp at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
Q2 2023 Quanterix Corp Earnings Call Transcript
Aug 08, 2023

$25.4 (+16.89%)

Earnings
Quanterix Corp at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Q1 2023 Quanterix Corp Earnings Call Transcript
May 09, 2023

$17.5 (+1.21%)

Earnings
Quanterix Corp at Barclays Global Healthcare Conference Transcript
Mar 15, 2023
Q4 2022 Quanterix Corp Earnings Call Transcript
Mar 06, 2023

$13.59 (+12.13%)

Earnings
Quanterix Corp at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Q3 2022 Quanterix Corp Earnings Call Transcript
Nov 08, 2022

$9.33 (-3.32%)

Earnings
Q2 2022 Quanterix Corp Earnings Call Transcript
Aug 08, 2022

$16.49 (-5.61%)

Earnings
Quanterix Corp Annual Shareholders Meeting Transcript
Jun 23, 2022
Quanterix Corp at Goldman Sachs Global Healthcare Conference Transcript
Jun 16, 2022
Q1 2022 Quanterix Corp Earnings Call Transcript
May 10, 2022

$16.82 (-9.08%)

Earnings
Quanterix Corp at Barclays Global Healthcare Conference Transcript
Mar 15, 2022
Q4 2021 Quanterix Corp Earnings Call Transcript
Mar 01, 2022

$31.6 (-6.34%)

Earnings
Quanterix Corp at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2022
Q3 2021 Quanterix Corp Earnings Call Transcript
Nov 04, 2021

$56.3 (+1.06%)

Earnings
Q2 2021 Quanterix Corp Earnings Call Transcript
Aug 05, 2021

$56.96 (+3.30%)

Earnings
Quanterix Corp Annual Shareholders Meeting Transcript
Jun 24, 2021
Quanterix Corp at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021
Q1 2021 Quanterix Corp Earnings Call Transcript
May 05, 2021

$52.77 (+0.88%)

Earnings
Q4 2020 Quanterix Corp Earnings Call Transcript
Mar 02, 2021

$77.1 (-6.73%)

Earnings
Quanterix Corp at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Q3 2020 Quanterix Corp Earnings Call Transcript
Nov 05, 2020

$44.09 (+4.80%)

Earnings
Q2 2020 Quanterix Corp Earnings Call Transcript
Aug 04, 2020

$33 (+2.20%)

Earnings
Q1 2020 Quanterix Corp Earnings Call Transcript
May 05, 2020

$26.5 (-3.55%)

Earnings
Quanterix Corp at Needham Healthcare Conference Transcript
Apr 14, 2020
Q4 2019 Quanterix Corp Earnings Call Transcript
Mar 09, 2020

$19.3 (-9.30%)

Earnings
Quanterix Corp at JPMorgan Healthcare Conference Transcript
Jan 16, 2020
Q3 2019 Quanterix Corp Earnings Call Transcript
Nov 06, 2019

$19.29 (-5.07%)

Earnings
Quanterix Corp at Canaccord Genuity Growth Conference Transcript
Aug 07, 2019
Q2 2019 Quanterix Corp Earnings Call Transcript
Aug 06, 2019

$29.04 (-3.90%)

Earnings
Quanterix Corporation, UmanDiagnostics AB - M&A Call Transcript
Jun 26, 2019
Q1 2019 Quanterix Corp Earnings Call Transcript
May 09, 2019

$23.24 (+0.82%)

Earnings
Q4 2018 Quanterix Corp Earnings Call Transcript
Mar 07, 2019

$23.82 (+2.10%)

Earnings

Quanterix Corp at Goldman Sachs Alzheimer's Disease Day Transcript

Oct 03, 2023 / 04:15PM GMT

Release Date Price: $26.74 (+0.11%)

Transcript

Matthew Carlisle Sykes

Goldman Sachs Group, Inc., Research Division - Research Analyst

All right. We'll get started here as people kind of pick up their lunches and come in, but good afternoon. My name is Matt Sykes. I'm the life science tools and diagnostics analyst at Goldman Sachs. And I have the pleasure of welcoming Masoud Toloue, President and CEO of Quanterix to my right; and Joel Braunstein, Co-Founder and CEO of C2N on further to my right. These are 2 companies which are at the forefront of developing commercializing blood-based biomarker testing for Alzheimer's disease. Masoud and Joel, welcome.

Masoud Toloue

Quanterix Corporation - President, CEO & Director

Hey, Matt.

Matthew Carlisle Sykes

Goldman Sachs Group, Inc., Research Division - Research Analyst

So this is a discussion that I've been selfishly looking forward to for some time. Last week, my team published a deep dive on blood biomarker testing for Alzheimer's, where we developed a market model for Alzheimer's testing outlining a potential

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.